Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

被引：0

作者：

Chen, Christine ^{[1
]}

Garzon, Ramiro ^{[2
]}

Gutierrez, Martin ^{[3
]}

Jacoby, Meagan A. ^{[4
]}

Brown, Peter ^{[5
]}

Flinn, Ian ^{[6
]}

Stone, Richard M. ^{[7
]}

Savoie, Mary Lynn ^{[8
]}

Baz, Rachid ^{[9
]}

Gabrail, Nashat Y. ^{[10
]}

Wang, Michael ^{[11
]}

Martin, Peter ^{[12
]}

Siegel, David ^{[13
]}

Mau-Sorensen, Morten ^{[5
]}

Andreef, Michael ^{[14
]}

Marshall, Tracey ^{[15
]}

Saint-Martin, Jean-Richard ^{[15
]}

Carlson, Robert ^{[15
]}

Shacham, Sharon ^{[16
]}

Kauffman, Michael ^{[15
]}

Kuruvilla, John ^{[17
]}

机构：

[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] John Theurer Canc Ctr, Hackensack, NJ USA

[4] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA

[5] Univ Copenhagen Hosp, Rigshosp, DK-2100 Copenhagen, Denmark

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[8] Univ Calgary, Calgary, AB, Canada

[9] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA

[10] Gabrail Canc Ctr, Canton, OH USA

[11] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[12] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA

[13] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[15] Karyopharm Therapeut, Newton, MA USA

[16] Karyopharm Therapeut Inc, Newton, MA USA

[17] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] INTERIM ANALYSIS DATA FROM PHASE 2 STUDY ON EFFICACY, SAFETY & INTRATUMORAL PHARMACOKINETICS OF ORAL SELINEXOR (KPT-330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Lassman, A. B.
Bent, M. J. V. D.
Wen, P. Y.
Walenkamp, A.
Plotkin, S.
Kung, A.
Gardner, H.
Shacham, S.
Chudnovsky, A.
Mau-Sorensen, P. M.
NEURO-ONCOLOGY, 2017, 19 : 14 - 14
[32] PRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA)
Martignetti, J.
Razak, A. R. A.
Chen, Y.
Gabrail, N. Y.
Gericitano, J. F.
Camacho, C.
Pereira, E.
Evans, B.
Dottino, P.
McCauley, D.
Shacham, S.
Rashal, T.
Saint-Martin, J.
Shacham, E.
Vincent, D.
Kauffman, M.
Mirza, M. R.
Mau-Sorensen, M.
ANNALS OF ONCOLOGY, 2014, 25
[33] KPT-330, a selective small molecule inhibitor of nuclear export, is active in bone and soft tissue sarcoma.
Nair, Jayasree S.
Tap, William
Vasudeva, Shyamprasad Deraje
Sicklick, Jason K.
Kauffman, Michael
Shacham, Sharon
Schwartz, Gary K.
CANCER RESEARCH, 2013, 73 (08)
[34] Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers
Vergote, I.
Lund, B.
Havsteen, H.
Ujmajuridze, Z.
Van Nieuwenhuysen, E.
Haslund, C.
Juhler-Nottrup, T.
Neven, P.
Mau-Sorensen, M.
Berteloot, P.
Kranich, A.
Rashal, T.
Meade, J.
Landesman, Y.
Saint-Martin, J-R.
Wright, G.
Crochiere, M.
Shacham, S.
Kauffman, M.
Mirza, M. Raza
ANNALS OF ONCOLOGY, 2016, 27
[35] Results of a Phase 2 Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export (SINE) in 114 Patients With Gynaecological Cancers
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 8 - 10
[36] Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma
Tabe, Yoko
Harada, Masako
Miyamae, Yuka
Kazuno, Saiko
Fujimura, Tsutomu
Ueno, Takashi
Miida, Takashi
Konopleva, Marina
Andreeff, Michael
BLOOD, 2014, 124 (21)
[37] First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Razak, Albiruni R. A.
Soerensen, Morten Mau
Mahipal, Amit
Shacham, Sharon
Yau, Cindy Y. F.
Lassen, Ulrik Niels
McCauley, Dilara
Cooksey, Jennifer
Tan, David Shao Peng
Saint-Martin, Jean-Richard
Landesman, Yossi
Pond, Gregory
Oza, Amit M.
Kauffman, Michael
Siu, Lillian L.
Mirza, Mansoor Raza
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis
Camilli, Samuel
Lockey, Richard
Kolliputi, Narasaiah
CELL BIOCHEMISTRY AND BIOPHYSICS, 2023, 81 (3) : 421 - 426
[39] Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis
Samuel Camilli
Richard Lockey
Narasaiah Kolliputi
Cell Biochemistry and Biophysics, 2023, 81 : 421 - 426
[40] The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review
Landes, Jennifer R.
Moore, Stephen A.
Bartley, Brooke R.
Doan, Hung Q.
Rady, Peter L.
Tyring, Stephen K.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 2139 - 2155

← 1 2 3 4 5 →